Global Blood Therapeutics, Inc.
GBTDelisted Oct 5, 2022- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001629137
Global Blood Therapeutics, Inc. was delisted on Oct 5, 2022; its insiders filed their last Form 4 on Oct 6, 2022; 247 institutions reported holding it in 13F filings for Q3 2022, worth $4.67B in total; Soros Fund Management was the only superinvestor holding it.
Key figures
- Market cap
- –
- Not available
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 247
- Q3 2022, +53 vs. previous quarter
- 13F value
- $4.67B
- Reported value at the end of Q3 2022
- Superinvestors holding
- 1
- At the end of Q3 2022
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2021
- $194.7M
- +57.3% year over year
- Net income, FY2021
- -$303.1M
- No comparable prior period
- Free cash flow, FY2021
- -$260.0M
- No comparable prior period
- Revenue, Q2 FY2022
- $71.5M
- +50.5% year over year
Revenue flow, FY2021
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2021: $303.1M (155.6% of revenue).
Superinvestors holding GBT, Q3 2022
Go to the superinvestors tab1 superinvestor reports holding Global Blood Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Soros Fund Management
George Soros
0.0%
Global Blood Therapeutics, Inc.'s share of the portfolio
- Shares
- 1
- Value
- $0
Latest insider trades
See all insider tradesOpen-market purchases and sales by Global Blood Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 6, 2022 (view filing) | Sep 1 | 5 days | Farrow Jeffrey SChief Financial Officer | SSale | −31.4K | $68.00 | −$2.14M | −91.1%3.09K after | |
| Aug 19, 2022 (view filing) | Aug 18 | 1 day | Habibizad NazilaSee Remarks | SSale | −4.68K | $67.19 | −$314.3K | −34.4%8.92K after | |
| Jun 22, 2022 (view filing) | Jun 21 | 1 day | Pizzo Philip A.Director | SSale | −1.26K | $27.25 | −$34.3K | −12.1%9.11K after | |
| Jun 22, 2022 (view filing) | Jun 21 | 1 day | Svoronos DawnDirector | SSale | −1.91K | $27.24 | −$52.0K | −26.2%5.38K after | |
| Sep 10, 2021 (view filing) | Sep 9 | 1 day | Morrison Scott WDirector | SSale | −4.80K | $30.21 | −$145.0K | −61.2%3.04K after |
Top 10 13F holders, Q3 2022
See all 247 holdersThe largest institutional positions in Global Blood Therapeutics, Inc. at the end of Q3 2022; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 6,282,173 | $427.8M | 0.01% | +262,742+4.4% | Added |
| BlackRock Inc. | 4,749,863 | $323.5M | 0.01% | −22,528−0.5% | Reduced |
| Baker Bros. Advisors LP | 3,732,502 | $254.2M | 1.66% | 00.0% | Unchanged |
| Pentwater Capital Management LP | 3,200,000 | $217.9M | 3.30% | +3,200,000 | New |
| State Street Corp | 2,384,677 | $162.4M | 0.01% | −2,038,867−46.1% | Reduced |
| Perceptive Advisors LLC | 2,322,247 | $158.1M | 4.60% | −692,807−23.0% | Reduced |
| JPMorgan Chase & Co | 2,304,636 | $156.9M | 0.02% | +1,898,523+467.5% | Added |
| FIL Ltd | 2,263,000 | $154.1M | 0.20% | +2,263,000 | New |
| UBS Oconnor LLC | 2,238,787 | $152.5M | 1.75% | +2,238,787 | New |
| Goldman Sachs Group Inc | 1,706,600 | $116.2M | 0.03% | +1,033,433+153.5% | Added |
Politician trades
All politician trades in GBT1 member of Congress reported 2 trades in Global Blood Therapeutics, Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Apr 27, 2020 |  Donna E. Shalala House · FL | Sell | $1K-$15K |
| Apr 27, 2020 | Donna E. Shalala House · FL | Buy | $1K-$15K |
House · FL · Apr 27, 2020
Sell$1K-$15K
House · FL · Apr 27, 2020
Buy$1K-$15K